Loading...
•
Jun 30, 2023
Zimmer Biomet Q2 2023 Earnings Report
Reported a strong second quarter with sales and earnings growth, raised full-year financial guidance.
Key Takeaways
Zimmer Biomet announced its second quarter 2023 financial results, reporting net sales of $1.870 billion, a 4.9% increase over the prior year, and a 6.0% increase on a constant currency basis. Net earnings were $209.6 million, with diluted earnings per share at $1.00. The company has raised its 2023 financial guidance based on its business performance and innovation pipeline.
Second quarter net sales increased 4.9% to $1.870 billion, and 6.0% on a constant currency basis.
Second quarter diluted earnings per share were $1.00; adjusted diluted earnings per share were $1.82.
The company received U.S. FDA 510k clearance for ActivBraid™.
Zimmer Biomet was certified in multiple countries by Great Place to Work®.
Zimmer Biomet
Zimmer Biomet
Zimmer Biomet Revenue by Segment
Revenue by Segment
Knees Revenue
CapyFin.comHips Revenue
CapyFin.comS.E.T. Revenue
CapyFin.comTech/Data/Surgical Revenue
CapyFin.com Forward Guidance
The Company is providing the following updated full-year 2023 financial guidance:
Positive Outlook
- 2023 Reported Revenue Change: 6.5% - 7.0%
- Foreign Currency Exchange Impact: (0.5)%
- Adjusted Diluted EPS: $7.47 - $7.57
Revenue & Expenses
Visualization of income flow from segment revenue to net income